For an otherwise healthy adult with acute cervical muscle pain and no gastrointestinal ulcer disease, severe renal impairment, uncontrolled hypertension, or high cardiovascular risk, which is more appropriate: diclofenac or celecoxib?

Celecoxib is Preferred Over Diclofenac for Acute Cervical Muscle Pain

For an otherwise healthy adult with acute cervical muscle pain, celecoxib is the better choice due to its superior gastrointestinal safety profile and comparable cardiovascular risk to diclofenac, while maintaining equivalent analgesic efficacy.

Efficacy: Equivalent Pain Relief

Both medications provide similar anti-inflammatory and analgesic effects for musculoskeletal pain:

• Celecoxib and diclofenac demonstrate comparable efficacy in managing inflammatory pain conditions, with no clinically meaningful differences in pain control or functional improvement 1.
• Both agents work through COX-2 inhibition to reduce inflammation and pain, making them equally effective for acute cervical muscle pain 2.

Gastrointestinal Safety: Clear Advantage for Celecoxib

The most significant difference between these agents lies in gastrointestinal toxicity:

• Celecoxib causes gastroduodenal ulcers in only 4% of patients compared to 15% with diclofenac (p<0.001), representing a nearly four-fold reduction in ulcer risk 1.
• Gastrointestinal adverse events requiring withdrawal occur three times more frequently with diclofenac (16%) than celecoxib (6%) 1.
• Celecoxib is consistently associated with lower risk of both upper and lower GI complications compared to non-selective NSAIDs like diclofenac 3, 4.
• The FDA labeling for both drugs carries black box warnings for GI bleeding, but celecoxib's COX-2 selectivity spares COX-1-mediated gastroprotective prostaglandins 5.

Cardiovascular Safety: Comparable or Favorable for Celecoxib

Contrary to older concerns about COX-2 inhibitors, recent high-quality evidence demonstrates:

• Celecoxib shows similar or lower cardiovascular risk compared to diclofenac in large-scale trials 6.
• The PRECISION trial (24,081 patients) found celecoxib had significantly lower cardiorenal composite outcomes compared to ibuprofen (HR 0.67, p=0.001) and a trend toward lower risk than naproxen 6.
• Diclofenac carries 20% increased risk of major adverse cardiovascular events (MACE) compared to other older COX-2 inhibitors (aIRR 1.19,95% CI 1.10-1.28), driven primarily by cardiac death 7.
• Diclofenac and celecoxib have comparable cardiovascular risks when directly compared (aIRR 0.96,95% CI 0.85-1.08) 7.
• Both drugs carry FDA black box warnings for cardiovascular thrombotic events, myocardial infarction, and stroke 5.

Blood Pressure Effects: Celecoxib Causes Less Hypertension

Blood pressure destabilization is an important consideration:

• Celecoxib causes significantly fewer systolic blood pressure increases >20 mmHg compared to diclofenac 8.
• Celecoxib is associated with lower rates of new antihypertensive medication initiation compared to ibuprofen and similar agents 8.
• Etoricoxib shows greater propensity to destabilize blood pressure than either celecoxib or diclofenac, but celecoxib remains the most favorable 2.

Renal Safety: Advantage for Celecoxib

Renal function preservation is critical even in short-term use:

• In patients with mild prerenal azotemia, only 3.7% taking celecoxib experienced clinically important reductions in renal function, compared to 7.3% with diclofenac (p<0.05) 8.
• Celecoxib showed significantly lower rates of clinically significant renal events (0.71%) compared to ibuprofen (1.14%) and naproxen (0.89%) in the PRECISION trial 6.
• Both drugs are renally cleared and require monitoring, but celecoxib demonstrates a more favorable renal safety profile 9, 10, 4.

Dosing Considerations

For acute cervical muscle pain in an otherwise healthy adult:

• Celecoxib: 200 mg twice daily is the standard dose, with the option to use 400 mg twice daily for more severe pain 9.
• Diclofenac: 50-75 mg twice daily is typical dosing 10.
• Use the lowest effective dose for the shortest duration necessary, as recommended by the American Heart Association 5.

Important Caveats

• Both drugs are contraindicated in the perioperative setting of coronary artery bypass graft surgery 5.
• For patients requiring concomitant low-dose aspirin, be aware that celecoxib does not interfere with aspirin's antiplatelet effects, unlike some non-selective NSAIDs 3.
• Duration should be limited to 10 days or less for over-the-counter use without physician consultation 5.
• Elderly patients (>65 years) have 40-50% higher celecoxib exposure but dose adjustment is generally not necessary unless body weight is <50 kg 9.